Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies

27 Aug 2016

Abstract excerpt

The allele ɛ4 of apolipoprotein E (apoE4) is the most prevalent genetic risk factor for Alzheimer's disease (AD) and is therefore a promising therapeutic target. Human and animal model studies suggest that apoE4 is hypolipidated; accordingly, we have previously shown that the retinoid X receptor (RXR) agonist bexarotene upregulates ABCA1, the main apoE-lipidating protein, resulting in increased lipidation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cholesterol and Lipid Metabolism
Share to Drug Transport and Resistance Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27567858
DOI: 10.3233/jad-160467

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain PathologiesPMID 27567858Read ↗

Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.Semantic proximity Read ↗

Differential Effects of apoE4 and Activation of ABCA1 on Brain and Plasma Lipoproteins.Semantic proximity Read ↗

Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOESemantic proximity Read ↗

Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice.Semantic proximity Read ↗

ApoE Lipidation as a Therapeutic Target in Alzheimer’s DiseaseSemantic proximity Read ↗

Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.Semantic proximity Read ↗

Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.Semantic proximity Read ↗

Role of LXR and ABCA1 in the Pathogenesis of Alzheimers Disease -Implications for a New Therapeutic ApproachSemantic proximity Read ↗

Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk.Semantic proximity Read ↗

Identification and modification of amyloid-independent phenotypes of APOE4 mice.Semantic proximity Read ↗

Neuronal ApoE4 stimulates C/EBPβ activation, promoting Alzheimer’s disease pathology in a mouse modelSemantic proximity Read ↗

Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.